IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (currently amended) A compound of Formula I, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof:



(I)

wherein:

Z is ~~O or~~ N-R^9;

R^1 is -CH_2-R^J, and R^J is phenyl which is optionally substituted with from 1 to 4 substituents each of which is independently:

(1) -C_{1-4} alkyl,
(2) -O-C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} haloalkyl,
(5) halo,
(6) -CN,
(7) -$N(R^A)R^B$,
(8) -$C(=O)N(R^A)R^B$,
(9) -$S(=O)R^A$,
(10) -SO_2R^A,
(11) -$N(R^A)SO_2R^B$,
(12) -$N(R^A)SO_2N(R^A)R^B$,
(13) -$N(R^A)C(=O)R^B$, or
(14) -$N(R^A)C(=O)$-$C(=O)N(R^A)R^B$;

~~R^1 is C_{1-6} alkyl substituted with R^J, wherein R^J is:~~

(A) aryl or aryl fused to a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the aryl or fused aryl is

(i) optionally substituted with from 1 to 5 substituents each of which is independently:

(1) $-C_{1-6}$ alkyl, which is optionally substituted with -OH, $-O-C_{1-6}$ alkyl, $-O-C_{1-6}$ haloalkyl, -CN, $-NO_2$, $-N(R^A)R^B$, $-C(=O)N(R^A)R^B$, $-C(=O)R^A$, $-CO_2R^A$, $-S(O)_nR^A$, $-SO_2N(R^A)R^B$, $-N(R^A)C(=O)R^B$, $-N(R^A)CO_2R^B$, $-N(R^A)SO_2R^B$, $-N(R^A)SO_2N(R^A)R^B$, $-OC(=O)N(R^A)R^B$, or $-N(R^A)C(=O)N(R^A)R^B$,

(2) $-O-C_{1-6}$ alkyl,

(3) $-C_{1-6}$ haloalkyl,

(4) $-O-C_{1-6}$ haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) $-NO_2$,

(9) $-N(R^A)R^B$,

(10) $-C(=O)N(R^A)R^B$,

(11) $-C(=O)R^A$,

(12) $-CO_2R^A$,

(13) $-SR^A$,

(14) $-S(=O)R^A$,

(15) $-SO_2R^A$,

(16) $-SO_2N(R^A)R^B$,

(17) $-N(R^A)SO_2R^B$,

(18) $-N(R^A)SO_2N(R^A)R^B$,

(19) $-N(R^A)C(=O)R^B$,

(20) $-N(R^A)C(=O)-C(=O)N(R^A)R^B$, or

(21) $-N(R^A)CO_2R^B$, and

(ii) optionally substituted with 1 or 2 substituents each of which is independently:

(1) aryl,

(2) $-C_{1-6}$ alkyl substituted with aryl,

(3) -HetA,

~~(4) -C(=O)-HetA; or~~

~~(5) -HetB;~~

~~wherein each HetA is independently a C4-7 azacycloalkyl or a C3-6 diazacycloalkyl, either of which is optionally substituted with from 1 to 3 substituents each of which is independently oxo or C1-6 alkyl; and~~

~~wherein each HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halo, -C1-6 alkyl, -C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, or hydroxy; or~~

~~(B) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; wherein the heteroaromatic ring is:~~

~~(i) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C1-6 alkyl, -C1-6 haloalkyl, -O-C1-6 alkyl, -O-C1-6 haloalkyl, or hydroxy, and~~

~~(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C1-6 alkyl substituted with aryl;~~

~~R2, R3, R4 and R5 are defined as follows:~~

~~(A) R2, R3, R4 and R5 are each independently:~~

R2 and R4 are each independently:

(1) -H,

(2) -C1-6 alkyl, which is optionally substituted with -OH, -O-C1-6 alkyl, -O-C1-6 haloalkyl, -CN, -N(RA)RB, -C(=O)N(RA)RB, -C(=O)RA, -CO2RA, -S(O)nRA, -SO2N(RA)RB, -N(RA)C(=O)RB, -N(RA)CO2RB, -N(RA)SO2RB, -N(RA)SO2N(RA)RB, -N(RA)C(=O)N(RA)RB, or -OC(=O)N(RA)RB,

(3) -C1-6 haloalkyl,

(4) CycA,

(5) AryA,

(6) HetC, or

(7) -C1-6 alkyl substituted with CycA, AryA, or HetC;

~~(B) R^2 and R^4 together with the carbon atoms to which each is attached form a carbon-carbon double bond; and R^3 and R^5 are each independently as defined in part A above;~~

~~(C) R^2 and R^3 together with the carbon atom to which they are both attached form a 3- to 8-membered saturated carbocyclic ring which is optionally substituted with from 1 to 4 substituents each of which is independently -OH, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl; and R^4 and R^5 are each independently as defined in part A above; or~~

~~(D) R^4 and R^5 together with the carbon atom to which they are both attached form a 3- to 8-membered saturated carbocyclic ring which is optionally substituted with from 1 to 4 substituents each of which is independently -OH, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl; and R^2 and R^3 are each independently as defined in part A above;~~

R^3 and R^5 are both H;

R^6 is:

(1) -H,

(2) -C_{1-6} alkyl, ~~which is optionally substituted with -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -N(R^A)R^B, -C(=O)N(R^A)R^B, -C(=O)R^A, -CO_2R^A, -S(O)$_n$$R^A$, -$SO_2$N($R^A$)$R^B$, -N($R^A$)C(=O)$R^B$, -N($R^A$)$CO_2R^B$, -N($R^A$)$SO_2R^B$, -N($R^A$)$SO_2$N($R^A$)$R^B$, -N($R^A$)C(=O)N($R^A$)$R^B$, or -OC(=O)N($R^A$)$R^B$,~~

(3) -C_{1-6} fluoroalkyl, ~~haloalkyl,~~

(4) CycA,

(5) AryA, or

~~(6) HetC, or~~

(6) ~~(7)~~ -C_{1-6} alkyl substituted with AryA; ~~CycA, AryA, or HetC;~~

R^7 is H or -C_{1-6} alkyl;

R^8 is ~~R^7 and R^8 are each independently:~~

(1) -H,

(2) -C_{1-6} alkyl, ~~which is optionally substituted with -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -N(R^A)R^B, -C(=O)N(R^A)R^B, -C(=O)R^A, -CO_2R^A, -S(O)$_n$$R^A$, -$SO_2$N($R^A$)$R^B$, -N($R^A$)C(=O)$R^B$, -N($R^A$)$CO_2R^B$, -N($R^A$)$SO_2R^B$, -N($R^A$)$SO_2$N($R^A$)$R^B$, -N($R^A$)C(=O)N($R^A$)$R^B$, or -OC(=O)N($R^A$)$R^B$,~~

(3) -CO_2R^A,
(4) -$C(=O)N(R^A)R^B$,
(5) -R^K,
(6) -$C(=O)$-R^K,
(7) -$C(=O)N(R^A)$-R^K, or
(8) -$C(=O)N(R^A)$-C_{1-6} alkylene-R^K;

~~(3) C_{1-6} haloalkyl,~~
~~(4) $C(=O)R^A$,~~
~~(5) CO_2R^A,~~
~~(6) $C(=O)N(R^A)R^B$,~~
~~(7) $N(R^A)SO_2N(R^A)R^B$,~~
~~(8) R^K,~~
~~(9) $C(=O)$-R^K,~~
~~(10) $C(=O)N(R^A)$-R^K,~~
~~(11) $C(=O)N(R^A)$-C_{1-6} alkylene-R^K, or~~
~~(12) C_{1-6} alkyl substituted with R^K, $C(=O)$-R^K, $C(=O)N(R^A)$-R^K, or $C(=O)N(R^A)$-C_{1-6} alkylene-R^K;~~

or alternatively R^7 and R^8 together with the carbon atom to which they are both attached form a 3- to 7-membered ~~3- to 8-membered~~ saturated carbocyclic ring; ~~ring which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, OH, C_{1-6} alkyl, C_{1-6} haloalkyl, O-C_{1-6} alkyl, or O-C_{1-6} haloalkyl;~~

R^9 is:

(1) -H,
(2) -C_{1-6} alkyl, ~~which is optionally substituted with OH, O-C_{1-6} alkyl, O-C_{1-6} haloalkyl, CN, $N(R^A)R^B$, $C(=O)N(R^A)R^B$, $C(=O)R^A$, CO_2R^A, $S(O)_nR^A$, $SO_2N(R^A)R^B$, $N(R^A)C(=O)R^B$, $N(R^A)CO_2R^B$, $N(R^A)SO_2R^B$, $N(R^A)SO_2N(R^A)R^B$, $N(R^A)C(=O)N(R^A)R^B$, or $OC(=O)N(R^A)R^B$,~~
(3) -C_{1-6} fluoroalkyl, ~~haloalkyl,~~
(4) CycA, or
~~(5) AryA,~~
~~(6) HetC, or~~
(5) ~~(7)~~ -C_{1-6} alkyl substituted with CycA, AryA, or HetC;

each n is independently an integer equal to zero, 1, or 2;

each R^A is independently H or C_{1-6} alkyl;

each R^B is independently H or C_{1-6} alkyl;

each R^K is independently CycA, AryA, or HetC;

each CycA is independently a C_{3-8} cycloalkyl, which is optionally substituted with from 1 to 4 substituents each of which is halogen, -OH, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, or -O-C_{1-6} haloalkyl;

each AryA is independently phenyl, ~~an aryl,~~ which is

~~(a)~~ optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkylene-OH, -C_{1-6} alkylene-O-C_{1-6} alkyl, -C_{1-6} alkylene-O-C_{1-6} haloalkyl, -C_{1-6} alkylene-$N(R^A)R^B$, -C_{1-6} alkylene-$C(=O)N(R^A)R^B$, -C_{1-6} alkylene-$C(=O)R^A$, -C_{1-6} alkylene-CO_2R^A, -C_{1-6} alkylene-$S(O)_nR^A$, -O-C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} haloalkyl, -OH, halo, -$N(R^A)R^B$, -$C(=O)N(R^A)R^B$, -$C(=O)R^A$, -CO_2R^A, -$S(O)_nR^A$, or -$SO_2N(R^A)R^B$~~, and~~ ; and

~~(b) optionally substituted with C_{3-8} cycloalkyl, aryl, HetD, or -C_{1-6} alkyl substituted with C_{3-8} cycloalkyl, aryl, or HetD;~~

each HetC is independently a 4- to 7-membered saturated or unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is

~~(a)~~ optionally substituted with from 1 to 4 substituents each of which is halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, OH, or oxo~~, and~~ .

~~(b) optionally substituted with C_{3-8} cycloalkyl, aryl, HetD, or -C_{1-6} alkyl substituted with C_{3-8} cycloalkyl, aryl, or HetD;~~

~~each HetD is independently a 4- to 7-membered saturated or unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S; and~~

~~each aryl is independently (i) phenyl or (ii) a 9- or 10-membered bicyclic, fused carbocylic ring system in which at least one ring is aromatic.~~

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (currently amended) The compound according to claim 1, ~~5,~~ or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, wherein R^6 is H.

7. (canceled)

8. (canceled)

9. (currently amended) A compound according to claim 1, which is a compound of Formula IIa ~~II,~~ or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof:



(IIa)



~~(II)~~

wherein:

X^1 and X^2 are each independently -H, -C_{1-4} alkyl, -O-C_{1-4} alkyl, -C_{1-4} haloalkyl, -O-C_{1-4} haloalkyl, halo, -CN, -$N(R^A)R^B$, -$C(=O)N(R^A)R^B$, or -$S(O)_nR^A$~~, wherein n is an integer equal to zero, 1, or 2~~;

R^2 and R^4 are each independently -H, -C_{1-4} alkyl, -C_{1-4} fluoroalkyl, C_{3-6} cycloalkyl, phenyl, or benzyl;

~~R^2, R^3, R^4 and R^5 are defined as follows:~~

~~(A) R^2 and R^4 are each independently -H, -C_{1-4} alkyl, -C_{1-4} fluoroalkyl, C_{3-6} cycloalkyl, phenyl, or benzyl; and R^4 and R^5 are both H;~~

~~(B) R^2 and R^4 together with the carbon atoms to which each is attached form a carbon-carbon double bond; and R^3 and R^5 are both H;~~

~~(C) R^2 and R^3 together with the carbon atom to which they are both attached form cyclopropyl; and R^4 and R^5 are both H; or~~

~~(D) R^4 and R^5 together with the carbon atom to which they are both attached form cyclopropyl; and R^2 and R^3 are both H;~~

R^6 is H, -C_{1-4} alkyl, CF_3, cyclopropyl, phenyl or benzyl;

R^7 is H or -C_{1-4} alkyl;

R^8 is -H, -C_{1-4} alkyl, -CO_2-C_{1-4} alkyl, -$C(=O)NH(C_{1-4}$ alkyl), -$C(=O)N(C_{1-4}$ alkyl$)_2$, C_{3-6} cycloalkyl, HetF, -C(=O)-HetE, or -$C(=O)N(R^A)$-$(CH_2)_{1-2}$-HetF; wherein

HetE is a 4- to 7-membered saturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms selected from 1 to 4 N atoms, zero or 1 oxygen atom, and zero or 1 sulfur atom, wherein the saturated heterocyclic is optionally substituted with from 1 to 3 substituents each of which is independently oxo or C_{1-4} alkyl; and with the proviso that the saturated heterocyclic is attached to the -C(=O)- via a ring N atom; and

HetF is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with 1 or 2 substituents each of which is independently a C_{1-4} alkyl;

or alternatively R^7 and R^8 together with the carbon atom to which they are both attached form a 3- to 6-membered saturated carbocyclic ring;

R^9 is -H, -C_{1-4} alkyl, -CH_2CF_3, -C_{3-6} cycloalkyl, -CH_2-C_{3-6} cycloalkyl, or -CH_2-phenyl;

each R^A is independently H or C_{1-4} alkyl; and

each R^B is independently H or C_{1-4} alkyl.

10. (currently amended) A compound according to claim 9, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, wherein:

X^1 and X^2 are each independently H, fluoro, chloro, methyl, trifluoromethyl, methoxy, CN, -SO_2CH_3, -C(=O)NH(CH_3), or -C(=O)N(CH_3)$_2$;

R^2 and R^4 are both H;

~~R^2, R^3, R^4 and R^5 are all H;~~

R^6 is H, methyl, cyclopropyl, or phenyl;

R^7 is H or methyl;

R^8 is -H, -C_{1-4} alkyl, -CO_2-C_{1-4} alkyl, -C(=O)NH(C_{1-4} alkyl), -C(=O)N(C_{1-4} alkyl)$_2$, C_{3-6} cycloalkyl, HetF, -C(=O)-HetE, or -C(=O)N(R^A)-(CH_2)$_{1-2}$-HetF; wherein

HetE is selected from the group consisting of:




, and

, wherein the asterisk * denotes the point of attachment to the -C(=O) moiety; and

HetF is selected from the group consisting of pyrrolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, pyridyl, pyrimidinyl, and pyrazinyl;

or alternatively R^7 and R^8 together with the carbon atom to which they are both attached form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; and

R^9 is H, methyl, ethyl, n-propyl, isopropyl, $-CH_2CF_3$, cyclopropyl, or $-CH_2$-cyclopropyl.

11. (currently amended) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

2-(4-fluorobenzyl)-8-hydroxy-5,5,6-trimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(4-fluorobenzyl)-8-hydroxy-5,5,6-trimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(-)-2-(4-fluorobenzyl)-8-hydroxy-5,5,6-trimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

2-(4-fluorobenzyl)-8-hydroxy-6-methyl-4a-phenyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-4a-phenyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(-)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-4a-phenyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

5-(tert-butyloxycarbonyl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

5-ethyl-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

6-(cyclopropylmethyl)-2-(4-fluorobenzyl)-8-hydroxy-5,5-dimethyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

5-(dimethylaminocarbonyl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof

2-(3-chloro-4-fluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(-)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclopentane-1,1'-[2,6]naphthyridine]-3',5'-dione;

(+)-6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclopentane-1,1'-[2,6]naphthyridine]-3',5'-dione;

(-)-6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclopentane-1,1'-[2,6]naphthyridine]-3',5'-dione;

2-(3,4-difluorobenzyl)-8-hydroxy-5,5,6-trimethy-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

6'-(4-fluorobenzyl)-4'-hydroxy-2'-methyl-6',7',8',8a'-tetrahydro-2' *H*-spiro[cyclobutane-1,1'-[2,6]naphthyridine]-3',5'-dione;

5-[(2-methylpropyl)aminocarbonyl]-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

5-(tert-butylaminocarbonyl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

5-[(2-pyridylmethyl)aminocarbonyl]-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof

5-(pyrimidin-2-yl)-2-(4-fluorobenzyl)-8-hydroxy-6-methyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione, and diastereomers and enantiomers thereof;

2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione;

(+)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione; and

(-)-2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione.

12. (previously presented) A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. (canceled)

14. (withdrawn) A method for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof.

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (currently amended) A pharmaceutical combination which is (i) a compound according to claim 1, or an individual enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, and (ii) an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors; wherein the compound of (i) or its pharmaceutically acceptable salt and the HIV infection/AIDS antiviral agent of (ii) are each employed in an amount that renders the combination effective for inhibiting HIV integrase, for ~~preventing or~~ treating infection by HIV, or for ~~preventing,~~ treating or delaying the onset of AIDS.